Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Cancer Res. 2016 Feb 26;76(7):1935–1941. doi: 10.1158/0008-5472.CAN-15-2406

Table 1.

Selected characteristics of cases and controls in the Multiple Myeloma Cohort Consortium*

Characteristic Cases Controls
No. of persons 624 (100) 1,246 (100)
Cohort
 Alpha-Tocopherol, Beta-Carotene Study (ATBC) 59 (9.5) 117 (9.4)
 Cancer Prevention Study II (CPS-II) 67 (10.7) 136 (10.9)
 Health Professionals Follow-up Study (HPFS) 28 (4.5) 55 (4.4)
 Melbourne Collaborative Cohort Study (MCCS) 52 (8.3) 106 (8.5)
 Nurses’ Health Study (NHS) 48 (7.7) 90 (7.2)
 PLCO Cancer Screening Triala 174 (27.9) 348 (27.9)
 Women’s Health Initiative (WHI) 196 (31.4) 394 (31.6)
Mean age at blood draw, years (SD) 63.9 (7.0) 63.9 (7.0)
Sex
 Female 355 (56.9) 708 (56.8)
 Male 269 (43.1) 538 (43.2)
Race
 White 568 (91.2) 1,138 (91.4)
 Black 35 (5.6) 68 (5.5)
 Other 20 (3.2) 39 (3.1)
Mean BMI at blood draw, kg/m2 (SD) 27.4 (5.0) 27.2 (4.9)
Type of blood sample
 EDTA plasma 288 (46.2) 579 (46.5)
 Heparin plasma 274 (43.9) 544 (43.7)
 Serum 62 (9.9) 123 (9.9)
Time from blood draw to diagnosis
 < 6 years 282 (45.2)
 ≥ 6 years 342 (54.8)
Median biomarker concentration (IQR)b
 Total adiponectin, μg/mL 11.5 (8.0-16.5)c 12.8 (8.6-17.8)
 High-molecular-weight (HMW) adiponectin, μg/mL 6.6 (4.3-10.1)c 7.4 (4.7-10.8)
*

Reported as frequency (%) unless otherwise noted

a

Analyzed separately in a previous investigation (13)

b

Reported as cohort- and sex-corrected analyte levels. Differences between cases and controls were also observed for uncorrected total and HMW adiponectin levels (P ≤ 0.005).

c

P ≤ 0.002 for cases vs. controls, Wilcoxon rank-sum test